Q3 2021 Investor Relations Results

Participants Financial review Conclusion Appendix Company overview Pharmaceuticals Oncology Financial performance Innovation: Pipeline overview Novartis submission schedule Supplementary indications for existing brands References Innovation: Clinical trials 2021 alpelisib BYL719 LCM PROS Beovu LCM brolucizumab, RTH258 DME Cosentyx 2022 secukinumab, AIN457 PSA IVIV Cosentyx secukinumab, AIN457 AS H2H 2023 LCM canakinumab ACZ885 Adjuvant NSCLC LCM Cosentyx 2024 LCM Adakveo SEG101 LCM Atectura LCM Sickle cell anaemia with crisis ped indacaterol + mometasone, QMF149 Asthma, pediatrics ≥2025 Cosentyx secukinumab, AIN457 Lichen Planus LCM Mayzent4 LCM siponimod, BAF312 Multiple sclerosis, pediatrics LCM Coartem LCM Aimovig LCM Jakavi LCM Piqray LCM secukinumab, AIN457 AS IVIV artemether + lumefantrine, COA566 Malaria uncompl., formula for <5kg erenumab, AMG334 ruxolitinib, INC424 alpelisib, BYL719 Pediatric Migraine Myelofibrosis (combination) HER2+ adv BC Cosentyx LCM secukinumab, AIN457 Juvenile idiopathic arthritis Cosentyx secukinumab, AIN457 Hidradenitis suppurativa LCM denosumab BioS Cosentyx LCM aflibercept BioS Kesimpta³ LCM Rydapt LCM GP2411 secukinumab, AIN457 SOK583 ofatumumab midostaurin, PKC412 anti RANKL mAb GCA Neovascular age-related macular degeneration Multiple sclerosis, pediatrics Acute myeloid leukemia, pediatrics Jakavi LCM Entresto EU¹ LCM Kisqali LCM Jakavi LCM Beovu LCM Kymriah LCM Zolgensma LCM ruxolitinib, INC424 sacubitril/valsartan, LCZ696 Chronic GVHD Pediatric CHF Jakavi LCM Tafinlar + Mekinist LCM ribociclib, LEE011 HR+/HER2- BC (adj) Lutathera ruxolitinib, INC424 brolucizumab, RTH258 tisagenlecleucel, CTL019 AVXS-101 OAV101 Pediatrics Acute GVHD Diabetic retinopathy 1L high risk ALL, pediatrics & young adults SMA IT LCM Jakavi LCM Cosentyx LCM Leqvio LCM ruxolitinib, INC424 Acute GVHD dabrafenib + trametinib, DRB436 HGG/LGG - Pediatrics 177 Lu-oxodotreotide² GEP-NET 1L G3 ruxolitinib, INC424 Pediatrics Chronic GVHD secukinumab, AIN457 Lupus Nephritis KJX839 CVRR-LDLC Kymriah LCM Xolair tisagenlecleucel, CTL019 r/r Follicular lymphoma omalizumab, IGE025 Auto-injector LCM Piqray alpelisib, BYL719 TNBC Piqray alpelisib, BYL719 Ovarian cancer Ped Hyperlipidemia LCM Tafinlar + Mekinist LCM Leqvio LCM KJX839 LCM dabrafenib + trametinib, DRB436 Thyroid cancer Promacta LCM eltrombopag, ETB115 r/r severe aplastic anemia Xolair LCM omalizumab, IGE025 Food allergy 1. Approved in US. 2. 177Lu-dotatate in US. 3. Kesimpta and Mayzent: pediatric study in multiple sclerosis run in conjunction (NEOS) 58 Investor Relations | Q3 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation